» Articles » PMID: 21484785

Nrf2 is Essential for Cholesterol Crystal-induced Inflammasome Activation and Exacerbation of Atherosclerosis

Overview
Journal Eur J Immunol
Date 2011 Apr 13
PMID 21484785
Citations 148
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidative stress and inflammation--two components of the natural host response to injury--constitute important etiologic factors in atherogenesis. The pro-inflammatory cytokine interleukin (IL)-1 significantly enhances atherosclerosis, however, the molecular mechanisms of IL-1 induction within the artery wall remain poorly understood. Here we have identified the oxidative stress-responsive transcription factor NF-E2-related 2 (Nrf2) as an essential positive regulator of inflammasome activation and IL-1-mediated vascular inflammation. We show that cholesterol crystals, which accumulate in atherosclerotic plaques, represent an endogenous danger signal that activates Nrf2 and the NLRP3 inflammasome. The resulting vigorous IL-1 response critically depended on expression of Nrf2, and Nrf2-deficient apolipoprotein E (Apoe)-/- mice were highly protected against diet-induced atherogenesis. Importantly, therapeutic neutralization of IL-1α and IL-1β reduced atherosclerosis in Nrf2+/- Apoe-/- but not in Nrf2-/- Apoe-/- mice, suggesting that the pro-atherogenic effect of Nrf2-signaling was primarily mediated by its permissive role in IL-1 production. Our studies demonstrate a role for Nrf2 in inflammasome activation, and identify cholesterol crystals as disease-relevant triggers of the NLRP3 inflammasome and potent pro-atherogenic cytokine responses. These findings suggest a common pathway through which oxidative stress and metabolic danger signals converge and mutually perpetuate the chronic vascular inflammation that drives atherosclerosis.

Citing Articles

Thirty years of NRF2: advances and therapeutic challenges.

Zhang D Nat Rev Drug Discov. 2025; .

PMID: 40038406 DOI: 10.1038/s41573-025-01145-0.


A review on NLRP3 inflammasome modulation by animal venom proteins/peptides: mechanisms and therapeutic insights.

Balde A, Benjakul S, Nazeer R Inflammopharmacology. 2025; .

PMID: 39934538 DOI: 10.1007/s10787-025-01656-7.


Targeting the NLRP3 inflammasome as a novel therapeutic target for osteoarthritis.

Karmakar V, Chain M, Majie A, Ghosh A, Sengupta P, Dutta S Inflammopharmacology. 2025; 33(2):461-484.

PMID: 39806051 DOI: 10.1007/s10787-024-01629-2.


Multitarget Effects of Nrf2 Signalling in the Brain: Common and Specific Functions in Different Cell Types.

Navarro E, Esteras N Antioxidants (Basel). 2025; 13(12.

PMID: 39765831 PMC: 11673142. DOI: 10.3390/antiox13121502.


Cholesterol crystals in the pathogenesis of atherosclerosis.

Baumer Y, Irei J, Boisvert W Nat Rev Cardiol. 2024; .

PMID: 39558130 DOI: 10.1038/s41569-024-01100-3.